E
Klotho Neurosciences, Inc. KLTO
$0.1817 $0.016710.12% NASDAQ
Recommendation
Prev Close
$0.165
Volume
651,620
Avg Vol (90D)
538,555
Market Cap
$4.70M
Dividend & Yield
--
52-Week Range
$0.1135 - $11.05
P/E (TTM)
--
EPS (TTM)
-$0.2853
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Klotho Neurosciences (NASDAQ:KLTO) Stock Price Down 4.7% - What's Next?
1/31/2025 - Ticker Report
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. ...
1/8/2025 - GuruFocus
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco
1/8/2025 - Globe Newswire
Klotho Neurosciences (NASDAQ:KLTO) and#038; ImmunityBio (NASDAQ:IBRX) Financial Review
12/21/2024 - Ticker Report
Klotho Neurosciences (NASDAQ:KLTO) Trading 6% Higher and#8211; Here's Why
12/18/2024 - Ticker Report
Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory Board
12/9/2024 - Globe Newswire
Former Merck USA President Joins Klotho Neurosciences' Board of Directors
12/3/2024 - GuruFocus
Former Merck USA President Joins Klotho Neurosciences' Board of Directors
12/3/2024 - Globe Newswire
Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor
10/23/2024 - Globe Newswire
Klotho Neurosciences names Peter Moriarty as COO
10/15/2024 - SeekingAlpha.com: All News
Klotho Neurosciences names Peter Moriarty as COO
10/15/2024 - The Fly
Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
10/15/2024 - Globe Newswire
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
9/30/2024 - Globe Newswire
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
9/30/2024 - Globe Newswire
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
9/17/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$5.79M
Net Income (TTM)
-$6.15M
Balance Sheet
Total Assets (Q)
$2.46M
Total Debt (Q)
$240.80K
Total Liabilities (Q)
$1.27M
Book Value Per Share (Q)
$0.0438
Cash Flow
Cash from Operations (TTM)
-$2.95M
Cash from Investing (TTM)
-$123.50K
Cash from Financing (TTM)
$3.13M
Net Change in Cash (TTM)
$60.90K
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Jun 16 and 20 (est)
Price History
Loading...
Beta
1.46
7-Day Total Return
16.47%
30-Day Total Return
-35.08%
60-Day Total Return
-52.31%
90-Day Total Return
-59.71%
Year to Date Total Return
-74.02%
1-Year Total Return
-97.07%
2-Year Total Return
-98.24%
3-Year Total Return
-98.16%
5-Year Total Return
--
52-week Low
Apr 04, 2025 - $0.1135
52-week High
May 07, 2024 - $11.05
Valuation
Market Cap
$4.70M - Nano Cap
Enterprise Value
$4.88M
Price/Sales (TTM)
--
Price/Book (Q)
3.77
Dividends and Shares
Shares Outstanding
27.22M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
klothoneuro.com
Phone Number
833 931 6330
Address
13576 Walnut Street
Omaha, NE 68144
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates comprise KLTO-101 for the... more
NASDAQ 05/01/2025 3:57PM Eastern Quotes delayed